Finland state

Paras Biopharmaceuticals Finland Oy has been identified as one of the “fastest growing companies in the Nordic biotechnology therapy and diagnostics industry”

Oulu, Finland, September 01, 2022 –(– Paras Biopharmaceuticals has a strong and consistent track record in offering end-to-end biological CDMO services, complex biological product development, including the development and licensing of biosimilars. Plimsoll Publishing is a group of industry-specific analysis experts, providing comprehensive coverage reports on company health assessments, business performance, market trends, benchmarking and call for action. ‘acquisition. Plimsoll also provides global and continental analysis in over 1600 different industries.

Plimsoll Analysis classified Paras Biopharmaceuticals Finland Oy as:

One of the most profitable companies, listed in the “Top 50 Gross Profits”.

High potential to increase the value of the company.
One of 52 companies identified as top potential acquisition targets.
Rated above average for enterprise value.
Considered in many outstanding performance categories.
Gross profit of Paras Biopharmaceuticals constant for the last 3 consecutive years.
Sales per employee well above industry average.

“It is a pleasure to see that the Plimsoll Publishing analysis has identified Paras Biopharmaceuticals in the Nordic region. It is a validation of the company’s efforts on the growth of Paras Biopharmaceuticals. The company’s CDMO revenues are growing and the Paras Biopharmaceuticals team is serving very valuable projects for companies in the US and Europe,” said Dr. Ashesh Kumar, CEO of Paras Biopharmaceuticals Finland Oy.

“Paras Biopharmaceuticals has a strong pipeline of biosimilars and the potential licensing of these assets will bring new growth opportunities to the company and make Paras Biopharmaceuticals a very unique company with a special position. We are a strong contributor to some valuable US-based companies as a biologics CDMO partner by providing solutions to unmet medical needs and achieving large-scale production,” adds Dr. Mark Jackson, Administrative Manager, Paras Biopharmaceuticals Finland Oy.

About Paras Biopharmaceuticals Finland Oy:
Paras Biopharmaceuticals Finland Oy has established its expertise in four critical areas by providing CDMOs of biologics, development and licensing of biosimilar production technologies, enabling the development of complex proteins from early stage to large scale, and the development of enzymes for medical purposes and bioprocesses.

Paras Biopharmaceuticals owns a 25,000 square foot state-of-the-art biologics production facility and is a revenue-generating, for-profit company with a proven track record serving innovative large pharma, mid-sized and small start-ups. companies in the United States and Europe for the development and production of small and large production batches of biological products

Paras Biopharmaceuticals has a fully equipped biologics production facility in Finland for the production of recombinant therapeutics in microbial systems. The state-of-the-art biologics production facility includes a total floor area of ​​25,000 sq. ft. and a classified clean room of 4,300 sq. ft. Other features include media and buffer preparation, live zone (fermentation and harvesting and extraction), purification suite (including +4°C cold room), final filtration and freeze-drying.

Paras Biopharmaceuticals has a strong portfolio of biologics and biosimilars in osteoporosis, rheumatoid arthritis, oncology and metabolic diseases. For more information, please visit the company’s website.